このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
Checkpoint Therapeutics 将来の成長
Future 基準チェック /26
Checkpoint Therapeuticsは、69.7%と94%でそれぞれ年率69.7%で利益と収益が成長すると予測される一方、EPSはgrowで71.4%年率。
主要情報
86.6%
収益成長率
87.3%
EPS成長率
Biotechs 収益成長 | 24.1% |
収益成長率 | 94.0% |
将来の株主資本利益率 | n/a |
アナリストカバレッジ | Low |
最終更新日 | 24 Jun 2024 |
今後の成長に関する最新情報
Recent updates
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Sep 20Checkpoint: Strong Data, But Comes With Risks
Sep 08Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M
Aug 12Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?
May 18Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions
Apr 18Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Feb 15Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results
Jan 28Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout
Nov 26Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans
Oct 30We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Jul 17Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data
Jul 14Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow
Jun 21Checkpoint surges 24% on B. Riley buy initiation, 567% upside potential
Jun 09It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year
Jun 02The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It
Mar 11Have Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Insiders Been Selling Their Stock?
Feb 06Do Institutions Own Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares?
Jan 27Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Dec 23What We Learned About Checkpoint Therapeutics' (NASDAQ:CKPT) CEO Pay
Nov 27Checkpoint Therapeutics +10% after expanding cosibelimab manufacturing deal with Samsung Biologics
Nov 02業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 96 | N/A | 30 | N/A | 1 |
12/31/2025 | 61 | -3 | -22 | N/A | 2 |
12/31/2024 | 0 | -45 | -59 | N/A | 3 |
3/31/2024 | 0 | -52 | -40 | -40 | N/A |
12/31/2023 | 0 | -52 | -48 | -48 | N/A |
9/30/2023 | 0 | -54 | -56 | -56 | N/A |
6/30/2023 | 0 | -59 | -53 | -53 | N/A |
3/31/2023 | 0 | -56 | -52 | -52 | N/A |
12/31/2022 | 0 | -63 | -58 | -58 | N/A |
9/30/2022 | 0 | -71 | -52 | -52 | N/A |
6/30/2022 | 0 | -72 | -47 | -47 | N/A |
3/31/2022 | 0 | -67 | -41 | -41 | N/A |
12/31/2021 | 0 | -57 | -26 | -26 | N/A |
9/30/2021 | 0 | -37 | -22 | -22 | N/A |
6/30/2021 | 0 | -31 | -20 | -20 | N/A |
3/31/2021 | 0 | -26 | -17 | -17 | N/A |
12/31/2020 | 1 | -23 | -17 | -17 | N/A |
9/30/2020 | 1 | -22 | -16 | -16 | N/A |
6/30/2020 | 1 | -22 | -15 | -15 | N/A |
3/31/2020 | 2 | -22 | -18 | -18 | N/A |
12/31/2019 | 2 | -25 | -21 | -21 | N/A |
9/30/2019 | 5 | -28 | -24 | -24 | N/A |
6/30/2019 | 4 | -32 | -27 | -27 | N/A |
3/31/2019 | 4 | -33 | -29 | -29 | N/A |
12/31/2018 | 4 | -36 | -26 | -26 | N/A |
9/30/2018 | 1 | -31 | -22 | -22 | N/A |
6/30/2018 | 1 | -27 | -20 | -20 | N/A |
3/31/2018 | 1 | -27 | -18 | -18 | N/A |
12/31/2017 | 2 | -23 | N/A | -15 | N/A |
9/30/2017 | 2 | -25 | N/A | -15 | N/A |
6/30/2017 | 2 | -24 | N/A | -14 | N/A |
3/31/2017 | 3 | -23 | N/A | -11 | N/A |
12/31/2016 | 3 | -22 | N/A | -10 | N/A |
9/30/2016 | 2 | -22 | N/A | -7 | N/A |
6/30/2016 | 2 | -21 | N/A | -7 | N/A |
3/31/2016 | 0 | -16 | N/A | -5 | N/A |
12/31/2015 | 1 | -14 | N/A | -1 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: CKPT今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: CKPT今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: CKPT今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: CKPTの収益 ( 94% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: CKPTの収益 ( 94% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: CKPTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です